503A Compounded Hormone Optimization: A Chemist's Guide to Supply Chain Integrity for HRT Clinics

Testosterone: Formulation and Potency Verification

Testosterone is available through 503A compounding in multiple delivery formats, each with distinct pharmacokinetic profiles and analytical requirements.

Injectable formats include testosterone cypionate and testosterone enanthate in various concentrations and carrier oils. Testosterone cypionate in cotton seed oil and grape seed oil, testosterone enanthate in grape seed oil, and testosterone propionate in grape seed oil are all available through ExaVeyra's pharmacy partner at concentrations ranging from 20 mg/mL to 200 mg/mL. The carrier oil selection affects injection site tolerability and the viscosity of the preparation, with grape seed oil generally better tolerated than cotton seed oil for subcutaneous administration.

Topical formats include testosterone creams across a wide concentration range from 10 mg/gram to 200 mg/gram. A 2024 multidisciplinary study published in Pharmaceutics demonstrated the clinical efficacy of compounded testosterone topical gel in a patient with late-onset hypogonadism, validating the UPLC assay testing method used to confirm potency and stability (Banov et al., Pharmaceutics, 2024. https://doi.org/10.3390/pharmaceutics16050621). The study confirmed that testosterone can penetrate into and through ex vivo human skin using the Franz finite dose model, and that the UPLC assay method demonstrated stability across the compounded formulation range.

The analytical benchmark for testosterone potency testing is HPLC or UPLC with UV detection. A COA that reports only a pass/fail potency result without the assay method, acceptance criteria, and analyst documentation does not provide sufficient information to verify the released concentration. The Fifth International Consultation on Sexual Medicine (2024) noted that published data have demonstrated significant variability of testosterone concentrations within compounded products, underlining the importance of rigorous analytical release testing (ICSM 2024, Sexual Medicine Reviews. https://doi.org/10.1093/smr/qxae122).

Estradiol and Progesterone: Women's Health Formulations

Estradiol is available through ExaVeyra's pharmacy partner in oral capsule formats from 0.25 mg to 2 mg, topical creams at 4, 6, and 10 mg/mL, and as Bi-Est combinations. Progesterone is available in immediate-release and sustained-release capsule formats from 25 mg to 300 mg, and in cream formulations at 50, 200, and 250 mg/mL.

The ACOG Clinical Consensus on Compounded Bioidentical Menopausal Hormone Therapy (November 2023) provides the most current evidence-based framework for clinicians evaluating compounded versus FDA-approved HRT options (ACOG Clinical Consensus No. 6, Obstetrics and Gynecology, 2023. https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy). The consensus document notes that FDA-approved bioidentical hormone preparations including estradiol and progesterone are available commercially and should be considered before prescribing compounded alternatives. Where compounded preparations are clinically indicated, the prescribing physician bears responsibility for ensuring the supplying pharmacy meets appropriate quality standards.

A 2025 narrative review on menopausal hormone therapy concluded that benefit-risk depends on timing, route, and dose, with initiation within 10 years of menopause and transdermal estradiol at low to moderate doses favored when cardiometabolic or thrombotic risk is a consideration (Arnautu et al., International Journal of Molecular Sciences, 2025. https://doi.org/10.3390/ijms262211098).

For potency testing, estradiol and progesterone preparations should be tested by HPLC with UV or fluorescence detection. Progesterone in sustained-release capsule formats requires dissolution testing in addition to potency assay to confirm the release profile matches the labeled specification.

The Bi-Est and Combination Formulations

Bi-Est combines estradiol and estriol in ratios of 80/20 or 50/50. ExaVeyra's pharmacy partner offers Bi-Est in cream formulations at 2 and 3 mg/mL and oral capsule formats at 1.25, 2.5, 5, and 6 mg. The Bi-Pro-Test cream combines Bi-Est, progesterone, and testosterone in a single topical preparation.

Combination preparations introduce additional analytical complexity. Each active ingredient requires its own potency assay, and the presence of multiple steroids in a single matrix can create analytical interference if the assay method is not appropriately validated for the specific combination. Clinicians should request individual potency results for each active ingredient, rather than a single combined assay pass, when evaluating COA documentation for multi-ingredient preparations.

Sermorelin

Sermorelin is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH). It is available through 503A compounding and has an established safety and tolerability profile in the literature. ExaVeyra's pharmacy partner offers sermorelin at 3 mg/mL (5 mL) and in combination with ipamorelin at 3 mg/3.6 mg per 5 mL. Sermorelin stimulates pituitary GH release through the GHRH receptor, producing physiological pulsatile GH secretion rather than the continuous supraphysiological levels associated with exogenous HGH administration.

Tesamorelin

Tesamorelin is an FDA-approved GHRH analog (Egrifta, approved for HIV-associated lipodystrophy) and is available through compounding partners at 3 mg/mL (5 mL) and 8 mg/mL (3 mL), and in combination with ipamorelin at 2.4 mg/1.2 mg per mL (5 mL). Its FDA-approved status provides a more established regulatory footing than non-approved secretagogues.

CJC-1295 and Ipamorelin: Current Regulatory Status

Clinicians and clinic operators should be aware of the active regulatory situation for these two compounds. In late 2023, the FDA added both CJC-1295 and ipamorelin to Category 2 of the Bulk Drug Substances list, which effectively prohibited compounding. In September 2024, both were removed from Category 2 pending further review by the Pharmacy Compounding Advisory Committee (PCAC). The PCAC reviewed ipamorelin in October 2024 and CJC-1295 in December 2024. As of the date of this article, neither compound has received a final determination restoring them to the 503A Bulks List.

ExaVeyra's pharmacy partner currently offers CJC-1295/ipamorelin as a combination preparation. Clinics should verify current regulatory status with their pharmacy partner and legal counsel before prescribing. The compound availability reflects the current PCAC review period and is subject to change upon final FDA determination.

The pharmacological rationale for the CJC-1295/ipamorelin combination is well-established in the research literature. Ipamorelin is a selective growth hormone secretagogue that activates the GHSR without the cortisol, ACTH, or prolactin co-stimulation seen with earlier GHRPs (Raun et al., European Journal of Endocrinology, 1998). CJC-1295 is a GHRH analog that increases the amplitude of GH pulses. The combination stimulates both the GHRH and ghrelin receptor pathways simultaneously, producing a synergistic GH release response.

Thyroid support

T4/T3 combination capsules in multiple ratios from 19 mcg/4.5 mcg to 152 mcg/36 mcg immediate-release formats are available for clinics managing thyroid optimization alongside sex hormone protocols.

Aromatase inhibitors

Anastrozole in 0.25, 0.5, and 1 mg capsule and tablet formats is available for managing estradiol conversion in testosterone-treated patients.

Fertility and gonadotropin support

Clomiphene in 25 and 50 mg capsules, enclomiphene in 12.5, 25, and 50 mg capsules, and HCG Pregnyl 10,000 IU are available for fertility preservation protocols in testosterone-treated patients.

DHEA

Available in 25, 50, and 100 mg capsule formats for adrenal hormone support.

Oxytocin

Available as 50 IU and 120 IU troches and 100 IU/mL nasal spray for practices incorporating bonding and intimacy support into hormone optimization protocols.

Sexual function

Sildenafil, tadalafil, and vardenafil in multiple formats and concentrations are available, including combination sildenafil/tadalafil capsules, sustained-release formats, and troches.

Potency assay methodology

Every steroid hormone preparation should have a COA that specifies the analytical method (HPLC or UPLC with detector type and wavelength), the acceptance criteria, the analyst or laboratory identity, and the specific potency result for the released lot. A COA that states only meets specification without the underlying data leaves the released concentration unverified.

Beyond-use dating with stability data

Compounded preparations do not carry FDA-validated expiration dates. The beyond-use date (BUD) assigned by the pharmacy should be based on stability testing for the specific formulation, not on USP default BUD tables, which are conservative estimates rather than formulation-specific determinations.

Sterility testing for injectable preparations

All injectable testosterone and peptide preparations must be released with sterility testing results under USP 71 or equivalent. The test must be performed on the specific lot, not on a production process validation batch.

Endotoxin testing for injectables

Quantitative endotoxin results by LAL assay with stated acceptance criteria in EU/mL are required for all injectable preparations. A qualitative pass result without the quantitative value and the assay acceptance limit is incomplete documentation.

API sourcing documentation

The active pharmaceutical ingredient used in the compounded preparation should be sourced from an FDA-registered API manufacturer with a USP or NF certificate of analysis. Request the API COA or ask the pharmacy to confirm the API source as part of your supplier qualification process.